Dose response and antihypertensive efficacy of the AT 1 receptor antagonist telmisartan in patients with mild to moderate hypertension

Advances in Therapy

Volumn 15, Issue 4, 1998, Pages 206-217

  Neutel, Joel M ^a  

^a Orange County Heart Institute and Research Center   (United States)

Author keywords

Dose ranging study; Efficacy; Pharmacokinetics; Telmisartan; Tolerability

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; TELMISARTAN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; HYPERTENSION; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; VERTIGO;

EID: 0031660677     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (3)

1. Timmermans PBMWM, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev. 1993;45:205-251.
2. Wienen W, Hauel N, vanMeel JC, Narr B, Ries U, Entzeroth M. Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR277. Br J Pharmacol. 1993;110:245-252.
3. Weijenberg MP, Feskens EJ, Kromhout D. Blood pressure and isolated systolic hypertension and the risk of coronary heart disease and mortality in elderly men (the Zutphen Elderly Study). J Hypertens. 1996;14:1159-1166.